VERU-111

• CAT Number: I018742
• CAS Number: 1332881-26-1
• Molecular Formula: C₂₁H₁₉N₃O₄
• Molecular Weight: 377.39
• Purity: ≥95%

VERU-111 (CAT: I018742) is a novel, orally active, and selective small molecule inhibitor of the tubulin polymerization pathway. It disrupts microtubule dynamics, leading to cell cycle arrest and inhibition of cell proliferation. VERU-111 has shown potent antiproliferative activity against various cancer cell lines, including taxane-resistant and multidrug-resistant tumors. It has also demonstrated efficacy in preclinical models of prostate, breast, and ovarian cancers. VERU-111 has the potential to overcome resistance to taxanes and other microtubule-targeting agents, making it a promising candidate for the treatment of chemotherapy-resistant cancers.

Reference

[1]. Wang Q, et al. Structure-Guided Design, Synthesis, and Biological Evaluation of (2-(1H-Indol-3-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl) Methanone (ABI-231) Analogues Targeting the Colchicine Binding Site in Tubulin. J Med Chem. 2019 Jul 12.[2]. Qinghui Wang, et al. Discovery of ABI-231 analogs targeting the colchicine site in tubulin for advanced melanoma. Cancer Research 76(14 Supplement):4848-4848.[3]. Vivek Kashyap, et al. ABI-231: A novel small molecule suppresses tumor growth and metastatic phenotypes of cervical cancer cells via targeting Human papilloma virus (HPV) E6 and E7. Cancer Research 78(13 Supplement):679-679.[4]. Kashyap VK, et al. Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer. J Exp Clin Cancer Res. 2019 Jan 23;38(1):29.